FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Mashinatan	D C	20540	
Washington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					of Section 30(f) of the investment company Act of 1940																			
Name and Address of Reporting Person* Woiwode Thomas							2. Issuer Name and Ticker or Trading Symbol Aligos Therapeutics, Inc. [ALGS]									(Check all applicable) X Director 10% (
(Last) (First) (Middle) C/O ALIGOS THERAPEUTICS, INC.								Trar	nsaction	ı (Mon	nth/Day/Year)			itle			pecify							
JKPUKA	II E	DRIVE, 2ND F	LUC	JK	1 If	Δmend	ment [ate	of Orig	inal Fi	iled (Month/Da	av/Vear)	\rightarrow	6 Ir	ndividual o	loint/G	roun Filir	na (Cher	rk Anı	nlicable				
t) TTH SAN NCISCO CA 94080					4. II Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person										
	(Sta	ite) (2	Zip)																					
		Table	I - N	lon-Deriva	tive	Secu	rities	Αc	quire	d, D	isposed of	f, or B	enefi	cia	lly Own	ed								
1. Title of Security (Instr. 3)			Date	Executi ear) if any		tion Date,		3. Transaction Code (Instr. 8)						5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Indire Bene Owne	ficial ership					
								Code	v	Amount (A) or (D)		Price	Transaction(s					(Instr. 4)						
Stock				06/11/20	21				J ⁽¹⁾		485,979	D	\$0.0	00	1,457	,937]]	See Foot	tnote ⁽²⁾				
Stock				06/11/202		21			J ⁽³⁾		9,719	A	\$0.0	9,719]	[See Footnote ⁽⁴⁾						
Stock				06/11/20	21				J ⁽⁵⁾		9,719	D	\$0.0	00 0			I		See Footnote ⁽⁴⁾					
Stock				06/11/20	21				J ⁽⁶⁾		8,383	A	\$0.0	00	8,38	8,383 I		[See Footnote ⁽⁷⁾					
Stock	06/11/2		06/11/20	21						8,383	D	\$0.0	00	0 I		[See Footnote ⁽⁷⁾							
Stock				06/11/20	21				J ⁽⁹⁾		2,226	A	\$0.0	00	4,452		4,452		Ι)				
Stock															862,4	2,444 I		862,444 I		I	See Footnote ⁽¹⁰⁾			
		Tal	ble I												y Owne	d								
		Date	Exec if an	cution Date,	4. Transaction Code (Instr. 8)		of Derivativ Securitie Acquired (A) or Disposed of (D)		Expiration (Month/Das		Date	Amount of Securities Underlying Derivative			Derivative Security	derivati Securiti Benefic Owned Followi Reporte Transac	ive ies ially ng ed ction(s)	Owners Form: Direct (or Indire	hip D) ect	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)			Expiration e Date	Title	or	er										
	SECURITY (Stock	(First GOS THER DRPORATE SAN ISCO CAISCO CAI	(First) (I GOS THERAPEUTICS, IN DRPORATE DRIVE, 2ND F SAN ISCO (State) (I Table Security (Instr. 3) Stock	(First) (Middle (GOS THERAPEUTICS, INC.) (SAN CA 94080 (State) (Zip) (Table I - N.) (Security (Instr. 3) (Stock (S	(First) (Middle) (GOS THERAPEUTICS, INC. DRPORATE DRIVE, 2ND FLOOR SAN (State) (Zip) Table I - Non-Derivate (Month/Day/No. Stock 06/11/20 Stock 06/11/20	Ali	Aligos A	Aligos Thera (First) (Middle) (GOS THERAPEUTICS, INC. DRPORATE DRIVE, 2ND FLOOR Table I - Non-Derivative Securities Security (Instr. 3) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) Stock 06/11/2021 Stock 06/11/2021	Conversion of Exercise of Conversion of Exercise of Conversion of Exercise of Executivy	Aligos Therapeutics, (First) (Middle) (GOS THERAPEUTICS, INC. DRPORATE DRIVE, 2ND FLOOR Table I - Non-Derivative Securities Acquires (Month/Day/Year) Table II - Derivative Securities Acquires (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic Table II - Derivative Securities Acquired (e.g., puts, calls, warrants, optic	Aligos Therapeutics, Inc.	Aligos Therapeutics, Inc. ALGS	Aligos Therapeutics, Inc. First (Middle)	Aligos Therapeutics, Inc. ALGS	Aligos Therapeutics, Inc. [ALGS]	Aligos Therapeutics, Inc. CALGS Check all agos Ch	Aligos Therapeutics, Inc. [ALGS]	Aligos Therapeutics, Inc. ALGS Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) X Director Officer (give title below) Check all applicable) Check all a	Aligos Therapeutics, Inc. ALGS	Aligos Therapeutics, Inc. ALGS				

- 1. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital VI, L.P. ("VVC VI") to its partners pursuant to a Rule 10b5-1 trading plan.
- 2. Shares held by VVC VI. Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP") is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VVC VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 3. Represents a change in the form of ownership of VV VI GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VVC VI.
- 4. Shares held by VV VI GP-GP is the general partner of VV VI GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held by VV VI GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
- 5. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP, to its partners.
- 6. Represents a change in the form of ownership of VV VI GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by VV VI GP.
- 7. Shares held by VV VI GP-GP. The Reporting Person is a managing member of VV VI GP-GP and may be deemed to share voting and dispositive power over the shares held VV VI GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 8. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV VI GP-GP, to its members.
- 9. Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration
- 10. Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP, L.P. ("VV I GP") is the general partner of VV I, and Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the general partner of VV I GP. The Reporting Person is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

<u>/s/ Robin L. Praeger,</u> <u>06/15/2021</u> <u>Attorney-in-fact for Thomas</u>

Woiwode

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.